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Abstract There is now a considerable body of data
supporting the hypothesis that aspirin could be effective in
the prevention and treatment of colorectal cancer, and a num-
ber of phase III randomised controlled trials designed to eval-
uate the role of aspirin in the treatment of colorectal cancer are
ongoing. Although generally well tolerated, aspirin can have
adverse effects, including dyspepsia and, infrequently, bleed-
ing. To ensure a favourable balance of benefits and risks from
aspirin, a more personalised assessment of the advantages and
disadvantages is required. Emerging data suggest that tumour
PIK3CA mutation status, expression of cyclo-oxygenase-2
and human leukocyte antigen class I, along with certain
germline polymorphisms, might all help to identify individ-
uals who stand to gain most. We review both the underpinning
evidence and current data, on clinical, molecular and genetic
biomarkers for aspirin use in the prevention and treatment of
colorectal cancer, and discuss the opportunities for further
biomarker research provided by ongoing trials.
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Introduction
Evidence for the anti-cancer effects of aspirin has emerged from
in vitro and animal models, epidemiological studies and
randomised data, with the most extensive evidence pertaining
to colorectal cancer (CRC). Research suggests that aspirin is
effective in primary prevention, reducing the risk of adenomas
[1] and CRC [2•, 3]. There is also evidence for a possible role in
the treatment of cancer, particularly in the adjuvant setting
(preventing recurrence and decreasing the likelihood of metas-
tases after potentially curative therapy) [4, 5•].
The potential benefits of aspirin have to be weighed against
the risk of adverse effects, particularly in the primary preven-
tion setting. Upper gastrointestinal symptoms (UGS) are a
common concern associated with aspirin use, and can limit
adherence, but are usually avoidable. The most undesirable
effect of aspirin is an increased bleeding tendency, which
can manifest as occult gastrointestinal bleeding, epistaxis or
purpura. Serious extra-cranial bleeding is rare (an estimated
3.6 additional events per 10,000 people treated for a year with
aspirin [6]), with the vast majority of bleeding episodes re-
solved without sequelae [7•], and intracranial haemorrhage is
rarer still (an estimated 0.8 additional events per 10,000 peo-
ple treated for a year with aspirin [6]).
Identifying biomarkers or clinical characteristics which
predict benefit from aspirin use could lead to a more targeted
intervention and protect some individuals from unnecessary
treatment and possible side effects. A number of potential
clinical, molecular and genetic biomarkers have been evaluat-
ed including the following: genes mutated in CRC (PIK3CA
and BRAF), molecules proposed to have a role in the mech-
anism through which aspirin exerts its anti-cancer effects (cy-
clo-oxygenase (COX) enzymes and human leukocyte antigen
(HLA) class I expression), and key genetic polymorphisms
that may influence the actions of aspirin.
This review will summarise the current data supporting a
personalised approach to aspirin use in relation to CRC and
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highlight the need to discover and validate biomarkers in on-
going trials. The article is structured into four sections: (i)
primary prevention of CRC, (ii) treatment of CRC, (iii) safety
biomarkers and (iv) other benefit-risk considerations.
Aspirin and Colorectal Cancer Prevention
The ability of aspirin to prevent colorectal carcinogenesis has
been observed in animal models [8–10]. The first clinical ev-
idence emerged in 1988 from a case-control study conducted
in Melbourne, Australia, which showed that aspirin reduced
the risk of developing CRC [11]. This finding was subse-
quently corroborated by several other epidemiological studies,
with a meta-analysis in 2012 of 30 case-control and cohort
studies (n=37,519 CRC cases) showing that aspirin was as-
sociated with a lower risk of developing CRC (relative risk
(RR) 0.73, 95 % confidence interval (CI), 0.67–0.79) [12].
Two large epidemiological studies have recently provided fur-
ther supporting data. The Association of American Retired
Persons Diet and Health study (AARP) included 301,240
adults aged between 50 and 71 years. An estimated 14 %
reduction in CRC was observed with daily aspirin use (hazard
ratio (HR) 0.86, CI 0.79–0.94) during 10 years of follow-up
[13]. A Danish case-control study of 10,280 CRC cases and
102,800 controls showed a reduction in the risk of CRC (odds
ratio (OR) 0.73, CI 0.54–0.99) for those continuously taking
aspirin for at least 5 years [14•].
Randomised data substantiate these observations, with a
meta-analysis of individual participant data on cancer inci-
dence in randomised trials designed to investigate the effect
of aspirin on vascular disease showing that aspirin reduced the
20-year risk of CRC by 24 % (HR 0.76, CI 0.63–0.94), im-
proving to 32 % if taken for ≥5 years (HR 0.68, CI 0.54–0.87)
[3]. Similarly, long-term follow-up from the Women’s Health
Study (WHS), a randomised placebo-controlled trial designed
to assess the effects of aspirin (100 mg on alternate days) in
the primary prevention of cardiovascular disease, showed that
allocation to aspirin reduced the incidence of CRC by 20 %
(HR 0.80, CI 0.67–0.97) [2•].
Recommending aspirin for all has been approached with
caution due to the difficulties of predicting the chance of ben-
efit, and the risk of toxicity on an individual level and there-
fore attention, has naturally turned towards individuals at
highest risk of CRC who may benefit most.
Aspirin and Colorectal Cancer Prevention: Who
Benefits?
Groups at the highest risk of developing CRC include those
with a hereditary CRC syndrome, a history of colorectal ade-
nomas or an inflammatory bowel disease. Aspirin can
exacerbate inflammatory bowel disease and is therefore
avoided, but there is evidence to support an effect of aspirin
in these other high-risk groups.
The most robust evidence exists for Lynch syndrome (hered-
itary non-polyposis colorectal cancer), the most common
inherited CRC syndrome. The CaPP2 (Cancer Prevention Pro-
ject 2) trial randomly allocated patients with Lynch syndrome to
600 mg daily aspirin or placebo and found a reduction in CRC
incidence in those that remained on aspirin for more than 2 years
(HR 0.41, CI 0.19–0.86, p=0.02) [15]. This is in the context of
an overall incidence of CRC in the CaPP2 trial population of
5.6 % (48/861) over 4.5 years of follow-up, and is likely to
represent the group with the highest absolute reduction in risk
of CRC. Intriguingly, a sub-analysis of this trial showed that the
increase in risk of CRC associated with obesity can be abrogated
by aspirin in this population [16•]. Obesity is, thus, a potential
predictive biomarker for aspirin benefit, and further research in
populations other than Lynch syndrome is warranted. Less evi-
dence is available to support an effect of aspirin in familial ade-
nomatous polyposis (FAP), another inherited CRC syndrome.
The CaPP1 trial randomised patients with FAP (prior to preven-
tive surgery), in a 2×2 factorial design, to 600 mg daily aspirin,
resistant starch or placebo. They found a trend towards reduced
polyp load in aspirin users; however, this did not reach statistical
significance (relative risk 0.77, CI 0.54–1.10) [17]. The median
duration of aspirin use was only 17months and it is plausible that
a treatment effect may have emerged with longer exposure.
Adenomas are precursor lesions for most cases of CRC,
and their prevention or regression has been proposed to rep-
resent a surrogate marker for CRC risk [18]. A meta-analysis
of four randomised controlled trials, including 2967 individ-
uals with previous adenomas or CRC (without an inherited
CRC syndrome), found that those allocated to aspirin had a
reduced risk of any subsequent adenoma (risk ratio 0.83, CI
0.72–0.96) or advanced adenoma (risk ratio 0.72, CI 0.57–
0.90) [1]. This corresponded to a reduction in the absolute risk
of any adenoma of 6.7 % (CI 3.2–10.2 %). Further research is
needed to confirm whether individuals with a history of ade-
nomas benefit more from aspirin than those without.
Whilst those at highest risk of CRC are most likely to gain
from chemoprevention with aspirin, it may be possible to
identify those that benefit in lower risk populations. Newly
emerging data show that aspirin users with certain single-
nucleotide polymorphisms (SNPs) have a reduced risk of de-
veloping CRC, and their absence may describe a group who
will not benefit. A case-control study of 840 CRC patients and
1686 matched controls examined CRC risk according to ex-
pression of the T allele of rs6983267, which is associated with
reduced WNT/β-catenin signalling, a major oncogenic path-
way in CRC, proposed to be affected by aspirin. They ob-
served that aspirin reduced CRC risk in the cohort as a whole
(OR 0.71, CI 0.60–0.85), but the effect was most marked in
individuals with a T allele of rs6983267 (OR 0.83, CI 0.74–
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0.94) [19••]. A larger case-control study (8634 cases, 8553
controls) examined the risk of CRC according to expression
of two different SNPs, rs2965667 (located close to the micro-
somal glutathione S-transferase 1 gene, often upregulated in
CRC) and rs16973225 (located close to the interleukin 16
gene, which has been implicated in CRC carcinogenesis)
[20••]. It was observed that use of aspirin and/or non-
steroidal anti-inflammatory drugs (NSAIDs) was associated
with a reduced risk of CRC amongst individuals with TT
genotype of SNP rs2965667 (OR 0.66, CI 0.61–0.70) and
the AA genotype of rs16973225 (OR 0.66, CI 0.62–0.71),
but not in those with other rarer genotypes. Germline genetic
polymorphisms have the potential to identify individuals that
benefit from aspirin, as well as those that do not, within pop-
ulations at lower risk of CRC, and further investigation using
existing datasets is required.
Aspirin and Colorectal Cancer Treatment
In vitro studies show that aspirin inhibits proliferation and
induces apoptosis in CRC cell lines [21, 22] suggesting a
possible role for aspirin in the treatment of CRC. Figure 1
summarises the results of the clinical studies investigating
the effect of aspirin use after a CRC diagnosis. The first epi-
demiological data emerged from the Nurses’ Health Study
(NHS) and Health Professionals Follow-up Study (HPFS)
showing that regular aspirin use after a diagnosis of CRC is
associated with a reduction in CRC deaths (HR 0.71, CI 0.53–
0.95) and overall mortality (HR 0.79, CI 0.65–0.97) [24]. This
has recently been corroborated by a large cohort of CRC pa-
tients from the Cancer Registry of Norway where improve-
ments in overall survival (HR 0.71, CI 0.68–0.75) and CRC-
specific survival (HR 0.53, CI 0.50–0.57) were seen with as-
pirin use after CRC diagnosis [25]. Similar improvements in
mortality were observed in data from the Eindhoven Cancer
Registry (ECR) (overall survival RR 0.77, CI 0.63–0.95) [26]
and in population data collected in Tayside, Scotland (overall
mortality HR 0.67, CI 0.57–0.79, and CRC-specific mortality
HR 0.58, CI 0.45–0.75) [27]. Observational data from the
CALGB 89803 trial (which compared two different adjuvant
chemotherapy regimens in patients with stage III colon can-
cer) has also shown a trend towards improved overall survival
(HR 0.63, CI 0.35–1.12) and disease-free survival (HR 0.68,
CI 0.42–1.11) in those patients using aspirin both during and
after chemotherapy [28•]. A study of 13,994 CRC patients
from the UK General Practice Research Database found a
strong trend towards a reduction in overall mortality; however,
this failed to reach significance (HR 0.91, CI 0.82–1.00) [29].
Data on cancer outcomes from randomised trials investi-
gating the effects of aspirin in vascular disease corroborate the
trends seen in epidemiological studies. A meta-analysis which
included 13,833 individuals who developed CRC in four vas-
cular trials has shown significant reductions in CRC deaths
(HR 0.66, CI 0.51–0.85) [3]. Another meta-analysis of five
vascular trials has shown that aspirin is associated with a re-
duction in the risk of having metastases when CRC is diag-
nosed (OR 0.36, CI 0.18–0.74) and of subsequently develop-
ing them during follow-up when not present at diagnosis (HR
0.26 CI 0.11–0.57) [30].
Rothwell 2012
6
 (146)
McCowan 2013 (2990)
Goh 2014 (726)
Bains 2015
3
 (25644)
Chan 2009 (1279)
Cardwell 2013
5
 (9089)
 CRC-specific mortality
Ng 2015
4
 (799)
McCowan 2013 (2990)
Bains 2015
3
 (25644)
Bastiaannet 2012 (1451)
Chan 2009 (1279)
Walker 2012
2
 (13944)
Cardwell 2013
2
 (12868)
 All-cause mortality
Outcome and study (n)
Randomised
Cohort
Cohort
Cohort
Cohort
Case-control
Cohort
Cohort
Cohort
Cohort
Cohort
Cohort
Cohort
design
Study
0.41 (0.20, 0.85)
0.58 (0.45, 0.75)
0.71 (0.43, 1.17)
0.53 (0.50, 0.57)
0.71 (0.53, 0.95)
1.06 (0.91, 1.23)
0.63 (0.35, 1.13)
0.67 (0.57, 0.79)
0.71 (0.68, 0.75)
0.77 (0.63, 0.95)
0.79 (0.65, 0.97)
0.91 (0.82, 1.00)
1.06 (0.94, 1.19)
(95% CI)
Risk statistic
1
Favours aspirin  Favours no aspirin
.25 .5 1 2
Fig. 1 Studies investigating CRC
outcomes according to aspirin use
following diagnosis. No summary
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high heterogeneity of studies.
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Aspirin and Colorectal Cancer Treatment: Who
Benefits?
Much of the work on potential biomarkers relating to aspirin use
as a treatment for CRC has come from three large cohorts (NHS
[24], HPFS [24] and ECR [26]). An initial analysis of the NHS/
HPFS dataset reported that the beneficial effects of aspirin on
CRC outcomes were restricted to individuals whose tumours
overexpressed COX-2 (HR 0.39, CI 0.20–0.76)and not observed
for those with weak or absent expression (HR 1.22, CI 0.36–
4.18) [24]. Whilst inhibition of either COX-1 or COX-2 is suffi-
cient to inhibit tumourigenesis in mousemodels [31], uncertainty
exists about the role of COX enzymes in relation to the anti-
cancer effects of aspirin, particularly given that the daily doses
of aspirin used in vascular prevention are not considered suffi-
cient for sustained COX inhibition in systemic tissues [32]. The
predictive utility of COX-2 has not been seen in other colorectal
studies [33••] or comparative studies in breast cancer [34].
Although the mechanism by which aspirin exerts its anti-
cancer effects remains unknown, one proposed hypothesis
was that aspirin, through its anti-platelet effects, could expose
circulating tumour cells to immune-mediated destruction by
natural killer cells [35] and that this effect would be restricted
to tumours with low or absent HLA class I expression. How-
ever, analyses of a random sample of colon tumour samples
(n=999) from the ECR found that the benefit from aspirin
therapy was largely restricted to tumours expressing HLA
class I antigens (risk ratio 0.53, CI 0.38–0.74), and was not
seen in those who had lost expression (risk ratio 1.03; CI
0.66–1.61) [33••]. This interesting observation, contrary to
the original study hypothesis, requires validation in further
datasets. HLA class I expression is seen in about a third of
colorectal tumours and so could identify a sizeable group who
might benefit from aspirin after a CRC diagnosis.
There has been significant interest in the phos-
phatidylinositol 3-kinase (PI3KCA) gene as a potential bio-
marker of aspirin response (Table 1). This follows the publi-
cation of data from the NHS/HPFS demonstrating that indi-
viduals with PIK3CA mutations taking regular aspirin after a
diagnosis of CRC had markedly improved CRC-specific sur-
vival (HR 0.18, CI 0.06–0.61) compared to those with wild-
type tumours (HR 0.96, CI 0.69–1.32). The same association
was observed for overall survival (mutated PIK3CA HR 0.54,
CI 0.31–0.94, wild-type PIK3CA HR 0.94, CI 0.75–1.17)
[36]. This finding was supported by a small ad hoc analysis
of the randomised VICTOR trial, where rofecoxib (a Cox-2
inhibitor) was being evaluated after CRC resection but the trial
was closed early when rofecoxib was withdrawn from the
market. Individuals with PIK3CA mutations taking regular
aspirin after diagnosis had improved recurrence rates (HR
0.11, CI 0.001–0.83), whereas those lacking PIK3CA muta-
tion did not (HR 0.92, CI 0.60–1.42), although the number of
participants taking aspirin with the mutation was small
(n=14) [37•]. However, data from two recent studies has not
confirmed the association. In the ECR dataset, the survival
benefit associated with aspirin use after a colon cancer diag-
nosis was seen in those with wild-type PIK3CA tumours (rate
ratio 0.55, CI 0.40–0.75), as well as those with PIK3CA-
mutated tumours where there was a trend towards a survival
benefit but this did not reach statistical significance (rate ratio
0.73, CI 0.33–1.63) [33••]. In addition, in a cohort of patients
with PIK3CA-mutated CRCs from the Moffitt Cancer Centre
and Royal Melbourne Hospital (n=1487), no overall survival
benefit was observed (HR 0.96, CI 0.58–1.57) and, whilst
there was a trend towards a CRC-specific survival benefit, this
was not significant (HR 0.60, CI 0.34–1.16) [38•]. PIK3CA
mutations only occur in 10–15 % of patients with CRC,
whereas the epidemiological data suggest that a greater
Table 1 Studies examining PIK3CA mutation, aspirin use and colorectal cancer outcomes
Study PIK3CA
mutation (%)
PIK3CA mutant PIK3CAwild type
No
aspirin
Aspirin Outcome HR 95 % CI
p value
No aspirin Aspirin Outcome HR 95 % CI
p value
NHS and
HPFS [36]
16.7 95 66 OS 0.54 0.31–0.94 p = 0.01 466 337 OS 0.94 0.75–1.17 p= 0.96
CSS 0.18 0.06–0.61 p < 0.001 CSS 0.96 0.69–1.32 p= 0.76
VICTOR
trial [37•]
11.6 90 14 OS 0.29 0.04–2.33 p = 0.19 681 111 OS 0.95 0.56–1.61 p= 0.26
CSS 0.11 0.001–0.83 p = 0.027 CSS 0.94 0.59–1.49 p= 0.79
MCS and
RMH [38•]
12.4 136 49 OS 0.96 0.58–1.57 p = 0.86 Study of PIK3CA-mutated tumours only
CSS 0.60 0.34–1.16 p = 0.14
ECRa [33••] 15.8 73 27 OS 0.73b 0.33–1.63 p = 0.4 348 147 OS 0.55 0.40–0.75 p< 0.001
Multivariate (adjusted) statistics are presented in all cases
OS overall survival, CSS colorectal cancer-specific survival, RFS recurrence-free survival, NHS Nurses’ Health Study, HPFS Health Professionals
Follow-up Study, MCS Moffitt Cancer Centre, RMH Royal Melbourne Hospital, ECR Eindhoven Cancer Registry, HR hazard ratio
a Colon cancer only
b Rate ratio
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proportion of CRC patients benefit from aspirin use after a
CRC diagnosis; therefore, this biomarker needs further inves-
tigation, ideally in randomised trials.
A cohort of 1226 patients with a diagnosis of CRC from the
NHS and HPFS have also been analysed for BRAF mutation
status. The effect of aspirin, after a cancer diagnosis, on
cancer-specific and overall survival did not differ according
to BRAFmutation status, but may have lacked statistical pow-
er. Interestingly, in terms of cancer prevention, aspirin was
associated with a lower risk of developing a BRAF wild-
type CRC (HR 0.73, CI 0.64–0.83), but not with BRAF-
mutated CRC (HR 1.03, CI 0.76–1.38) [39•].
The risk of CRC recurrence after potentially curative treat-
ment depends on a number of prognostic factors, which in-
clude stage, mode of presentation, microsatellite instability
status and whether adjuvant chemotherapy was administered.
Any relative improvement in CRC outcomes with aspirin will
need to be considered in the context of an individual’s abso-
lute risk of recurrence.
Identifying Those at Risk of Toxicity
Aspirin has been used for over 100 years [40] and has a well-
documented toxicity profile. Standard contraindications to as-
pirin use include the following: a history of active or recurrent
peptic ulceration, active gastrointestinal bleeding, previous
intracranial haemorrhage, a haemorrhagic diathesis or a coag-
ulation disorder. Avoiding co-administration of other
NSAIDs, anti-coagulants or corticosteroids also reduces the
risk of adverse effects [41].
UGS are common side effects associated with aspirin, with
one survey reporting 15.4 % (n=152/986) of long-term low-
dose aspirin users experiencing UGS [42]. A history of gastro-
oesophageal reflux disease or dyspepsia prior to starting aspi-
rin has been shown to be strongly predictive of UGS on aspi-
rin (OR 17.6, CI 11.52–26.88) [42]. Helicobacter pylori in-
fection has been proposed to be a marker of increased risk of
developing dyspepsia and a bleeding gastrointestinal ulcer
with aspirin [7•]; however, most data supporting this associa-
tion relates to non-aspirin NSAID use; and therefore, further
data is needed to confirm a relationship with aspirin [43]. The
HEAT trial (ISRCTN10134725), examining H. pylori eradi-
cation to prevent ulcer-related bleeding and dyspepsia in as-
pirin users, is ongoing.
The most common cause for concern in relation to aspirin
use is the risk of bleeding. Data from six cardiovascular pri-
mary prevention RCTs (n=95,000) estimated that aspirin in-
creased the risk of serious bleeding (excluding intracranial
haemorrhage) by 0.04 % per year (from 6.6 events per year
in 10,000 individuals to 10.2 events [6]). Age has been shown
to be a key predictor of bleeding risk with a recent systematic
review estimating that the risk of major bleeding increases
between three- and fourfold between the ages of 50–54 and
70–74 years [7•]. Intracranial haemorrhage is even rarer with
aspirin estimated to increase the risk by less than 0.01 % per
year (from 2.7 events in 10,000 individuals treated for a year
in the control groups to 3.5 events in the aspirin groups, HR
1.39, CI 1.08–1.78) in the aforementioned analysis of six car-
diovascular RCTs of aspirin. This study also revealed that
mean blood pressure is associated with an increased risk of
intracranial haemorrhage (rate ratio 2.18, CI 1.65–2.87) [6].
Certain genetic polymorphisms have been proposed as po-
tential biomarkers for NSAID-induced gastrointestinal ulcer-
ation and bleeding. A study in a Japanese population (n=480)
found that a functional SNP of the COX-1 gene (rs1330344)
has been shown to be significantly associated with gastric
ulceration (OR 5.80, CI 1.59–21.1) [44]. Additionally, two
polymorphisms of CYP2C9 (an enzyme responsible for the
metabolism of aspirin) have been found to be significantly
associated with bleeding risk in NSAID users [45, 46].
Biomarkers including increasing age, previous dyspepsia
and certain SNPs have the potential to identify those at
greatest risk of aspirin toxicity. Furthermore, diagnosing and
treating conditions like hypertension and H. pylori infection
could also reduce the change of adverse effects.
Other Benefit-Risk Considerations
Aspirin is an established treatment for the secondary prevention
of cardiovascular disease but is not generally recommended for
its primary prevention, however a recommendation for its use in
both the prevention of cardiovascular disease and cancer is cur-
rently under consideration by the United States Preventive Ser-
vices Task Force [47]. Little is known about the cardiovascular
benefits of aspirin in those with cancer as this is an exclusion
criterion in most large cardiovascular trials. CRC and cardiovas-
cular disease have a number of common risk factors, including
obesity, high cholesterol and diabetes, and any cardiovascular
benefits might add to the rationale for aspirin use in the context
of CRC prevention or treatment. Data from cardiovascular trials
has additionally suggested that some individuals are resistant to
the biological effects of aspirin [48] which also has the potential
to limit anti-cancer activity. The existence of aspirin resistance is
challenged by the finding that serum thromboxane B2 (a serum
marker of platelet activation) is suppressed by aspirin in 99 % of
healthy subjects [49]. Other explanations to account for the phe-
nomena include variability in some functional assays of platelet
function or undetected poor adherence to aspirin [50]. Fast re-
covery of platelet function in some individuals might have pre-
viously been categorised as resistance, and this might be ad-
dressed with twice daily doses [51]. Both the cardiovascular
effects of aspirin and the possibility of aspirin resistance could
alter the overall risk-benefit profile, and thus require further in-
vestigation in existing datasets and ongoing trials.
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Conclusions
The current data on the benefits and risks of prophylactic aspirin
in the general population has recently been reviewed by Cuzick
et al. who concluded that aspirin use for greater than 5 years (75–
325 mg/day), starting between the ages of 55 and 65, has a
favourable benefit-harm profile [52••]. Phase III trials investigat-
ing the role of aspirin for cancer prevention in the general pop-
ulation are likely to be challenging due to the length of follow-up
and number of participants required. However, in higher risk
groups, trials are more feasible. The CaPP3 trial (Cancer Preven-
tion Project 3), examining different doses of aspirin for the pre-
vention of Lynch syndrome cancer (ISRCTN16261285), and the
seAFOod (Systematic Evaluation of Aspirin and Fish Oil Bowel
Polyp Prevention Trial), examining the effect of aspirin and fish
oil in patients at high risk of colorectal adenomas
(ISRCTN05926847), are ongoing and the results are awaited.
The role of aspirin in the treatment of CRC is also being
evaluated in a number of recruiting phase III trials. Add-
Aspirin (ISRCTN74358648) is a double-blind placebo-con-
trolled trial for patients with colorectal, breast, gastro-
oesophageal and prostate cancer, investigating the effects of
aspirin in the adjuvant setting. Participants are randomised to
aspirin 300 mg, aspirin 100 mg or placebo for at least 5 years,
and it is separately powered for each tumour type to assess the
effects of tumour-specific outcomes. Other ongoing trials in
this setting include ASCOLT (Aspirin for Dukes C and High
Risk Dukes B CRCs, NCT00565708) and ASPIRIN (ATrial
of Aspirin on Recurrence and Survival in Elderly Colon Can-
cer Patients, NCT02301286). There are also three upcoming
trials investigating the effects of aspirin in molecularly strati-
fied groups. In the adjuvant setting, ALASCCA is a
randomised, double-blind, placebo-controlled phase III trial
of aspirin in colorectal patients with mutations in the PI3K
signalling pathway (PIK3CA, PIK3R1 or PTEN mutations),
and SAKK 41/13 (Swiss Group for Clinical Cancer Re-
search), a double-blind, placebo-controlled randomised trial
of adjuvant aspirin treatment in PIK3CA-mutated colon can-
cer patients (NCT02467582). In the advanced setting,
FOCUS4-B (ISRCTN90061546) plans to investigate the role
of aspirin in individuals with PIK3CAmutant advanced CRC.
Prior to being considered as an intervention in randomised
trials, aspirin has not followed the modern target-driven drug
development pathway taken by other anti-cancer agents. Conse-
quently, biomarker discovery and validation is at an early stage.
Ideally, predictive biomarkers are co-developed with a drug and
validated in phase I and II trials prior to defining the population
for phase III trials [53]. However, potential biomarkers for aspi-
rin have mostly emerged from observational studies where there
is a risk of confounding and, therefore, it is highly important that
they are investigated further in ongoing trials. Research into the
mechanisms underlying the anti-cancer effects of aspirin may
also reveal new biomarkers. The likelihood of a single
biomarker that can identify individuals that will or will not ben-
efit from aspirin is low, and thus, it will be important to inves-
tigate patterns of multiple biomarkers to select individuals who
will gain from aspirin therapy.
Aspirin is a low-cost, generic agent, available in both
resource-poor and resource-rich countries. If it can be shown
to be effective, there is the potential for a major impact on the
global burden of CRC. Identifying those who are most likely
to benefit will be essential to maximising this potential.
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